Redeye updates its view and outlook on Nanologica following the company’s year-end report and announ...
Q4 results Sales SEK 403m (0% vs ABGSCe 403m), EBITDA 71m (6% vs ABGSCe 67m), EBITA 44m (12% vs ABGS...
Redeye continues to be positive to Bredband2 following a solid Q4 report, where a higher-than-expect...
Redeye comments on last night’s news regarding Netmore’s acquisition of Senet, a North American-base...
Redeye reinforces its positive view of CombinedX following a strong Q4 report, with profitability be...
Spago Nanomedical's lead candidate Tumorad are progressing towards initial results by mid-2024 and P...
Mesdopetam EOP2 FDA meeting on 20 Feb, feedback 30 days later Pirepemat Ph 2b full enrolment in Q3'2...
Underwhelming performance continues in Q4 EBITA down 7-3%, lower in both segments Share trading at 1...
CapMan reported Q4 EBIT of -4.8m, clearly below Refinitiv consensus at EUR 6m.
Redeye’s initial take on the OPEX in Q4 being temporarily high is bolstered after a deeper dive into...
Redeye thinks that Lagercrantz yet again showed resiliency with strong margins and cash flow despite...
Suominen's Q4 comparable EBITDA remained virtually intact q/q, but fell short of Vara Research conse...
Board recommends shareholders to reject bid Q4 better than it looked at first glance 13x '24e EV/EBI...
Underlying earnings better than expected 4.2% organic sales growth in Q4 Near-term uncertainty persi...
Q4 NOI -2% vs ABGSCe Earnings capacity IFPM -3% vs ABGSC 2024e Higher DPS and reiterate acquisition ...
EBITA SEK 177m (-11% vs. ABGSCe, -9% vs. cons) We expect cons.
Q4e: 8% org. top line growth on tough comps Earnings growth remains very strong, adj.
Q4 EBITDA of 21.5m vs ABGSCe 20.1m Initiates strategic review of portfolio Downwards revision to con...
Suominen’s result were largely in line with Q3 and fell short of Vara Research consensus expectation...
More baseline falls vs. expected implies higher likelihood of effect New guidance: completion of stu...
.jpg)
